Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Leuk Lymphoma. 2019 Sep 23;61(2):387–396. doi: 10.1080/10428194.2019.1665664

Table 3.

Disease responses, n (%)

Best response All (n = 25) Elderly untreated (n=5) Relapsed/Refractory (n=20) 23 mg/m2 (n=7) 30 mg/m2 or 60mg fixed dose (n=11) 40 mg/m2 (n=4) 55 mg/m2 (n=3)
ORR (CR/CRi/MLFS) 10 (40) 4 (80) 6 (30) 2 (29) 4 (36) 3 (75) 1 (33)
CR 5 (20) 2 (40) 3 (15) 2 (29) 3 (27) 0 (0) 0 (0)
CRi 3 (12) 2 (40) 1 (5) 0 (0) 0 (0) 2 (50) 1 (33)
MLFS 2 (8) 0 (0) 2 (10) 0 (0) 1 (9) 1 (25) 0 (0)
SD 10 (40) 1 (4) 9 (45) 4 (57) 4 (36) 0 (0) 2 (67)
PD 1 (4) 0 (0) 1 (5) 0 (0) 1 (9) 0 (0) 0 (0)
NE 4 (16) 0 (0) 4 (20) 1 (14) 2 (18) 1 (25) 0 (0)

Abbreviations: CR, complete remission; CRi, complete remission with incomplete count recovery; MLFS, morphologic leukemia free state; NE.